Sequent Scientific Ltd's Q3FY25 Quarter Results
- 12 Feb 2025
Result Summary
- Sequent Scientific Ltd reported a 6.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 18.8%.
- Its expenses for the quarter were up by 7.6% QoQ and 15.8% YoY.
- The net profit increased 2.2% QoQ and decreased 39.3% YoY.
- The earnings per share (EPS) of Sequent Scientific Ltd stood at 0.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 396.65 | 373.16 | 333.88 | 6.3% | 18.8% |
Total Expenses | 388.24 | 360.94 | 335.15 | 7.6% | 15.8% |
Profit Before Tax | 8.10 | 7.90 | 1.49 | 2.5% | 443.6% |
Tax | 1.62 | 1.56 | -9.18 | 3.8% | -117.6% |
Profit After Tax | 6.48 | 6.34 | 10.68 | 2.2% | -39.3% |
Earnings Per Share | 0.10 | 0.10 | 0.30 | 0.0% | -66.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sequent Scientific Ltd is a prominent player in the pharmaceutical sector, primarily focusing on animal health products. The company specializes in veterinary medicines and aims to provide comprehensive solutions to improve animal health and productivity. As of the latest information, Sequent Scientific Ltd has been actively involved in expanding its product portfolio and market reach. However, specific recent developments are not available within the data set provided.
Revenue
During the third quarter of fiscal year 2025 (Q3FY25), Sequent Scientific Ltd reported a total income of ₹396.65 crores. This represents a quarter-over-quarter (QoQ) increase of 6.3% from ₹373.16 crores in Q2FY25. On a year-over-year (YoY) basis, the company experienced a significant growth of 18.8% compared to ₹333.88 crores in Q3FY24. This upward trend in total income indicates strong revenue performance over both the quarterly and annual comparison periods.
Profitability
Sequent Scientific Ltd's profitability metrics for Q3FY25 show a stable performance. The profit before tax (PBT) was recorded at ₹8.10 crores, reflecting a 2.5% increase from ₹7.90 crores in the previous quarter, Q2FY25. Compared to the same quarter in the previous year, Q3FY24, where PBT was just ₹1.49 crores, there is a remarkable YoY increase of 443.6%. The profit after tax (PAT) for Q3FY25 stood at ₹6.48 crores, which is slightly higher than the ₹6.34 crores in Q2FY25, marking a 2.2% QoQ increase. However, when compared to Q3FY24's PAT of ₹10.68 crores, there is a YoY decline of 39.3%.
Operating Metrics
The company's total expenses for Q3FY25 amounted to ₹388.24 crores, up by 7.6% from ₹360.94 crores in Q2FY25, and a 15.8% increase from ₹335.15 crores in Q3FY24. These rising expenses are aligned with the increase in total income, indicating a consistent operational scale. The earnings per share (EPS) for Q3FY25 remained constant at ₹0.10, the same as in Q2FY25, but decreased significantly by 66.7% from ₹0.30 in Q3FY24. This consistency in EPS despite the fluctuation in profit levels suggests a stable per-share performance over the recent quarter, albeit with a notable decline from the previous year.
